Scinai Immunotherapeutics Ltd. (SCNI): Capital Expenditures

Annual figures by period end, from SEC filings.

$24.0K

Year ended 2025-12-31

-69.4%

3-year compound annual growth

2021-12-31 Capital Expenditures (USD) 2025-12-31

Period ended	Capital Expenditures	Change YoY	Source filing
2025-12-31	$24.0K	+100.0%	2026-04-01, From 2025-01-01
2024-12-31	$12.0K	-98.1%	2026-04-01, From 2024-01-01
2023-12-31	$637.0K	-23.8%	2026-04-01, From 2023-01-01
2022-12-31	$836.0K	+501.4%	2025-05-07, From 2022-01-01
2021-12-31	$139.0K	n/a	2024-05-15, From 2021-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Capital Expenditures	Change YoY
Scinai Immunotherapeutics Ltd. (SCNI)	2025-12-31	$24.0K	+100.0%
Inhibrx Biosciences, Inc. (INBX)	2025-12-31	$31.0K	-98.8%
Pluri Inc. (PLUR)	2026-06-30	$633.0K	-60.9%
Prokidney Corp. (PROK)	2025-12-31	$15.20M	-48.5%
Humacyte, Inc. (HUMA)	2025-12-31	$884.0K	-43.8%
Aligos Therapeutics, Inc. (ALGS)	2024-12-31	$130.0K	+584.2%
Cardiff Oncology, Inc. (CRDF)	2025-12-31	$44.0K	-45.0%
Surrozen, Inc. (SRZN)	2025-12-31	$128.0K	+392.3%
CRISPR Therapeutics AG (CRSP)	2025-12-31	$914.0K	-51.9%

Compare SCNI, INBX, PLUR, PROK side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗